Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 November 2019 | Story Charlene Stanley | Photo Supplied
DIABETES read more
The modern clinical research facilities at FARMOVS where the two ground breaking diabetes studies will be conducted.

Diabetes is no longer seen simply as a disease, but as a worldwide epidemic, with alarming increases recorded in both developed and developing countries over the past few years.

About 3,5 million South Africans have diabetes, and many more are unaware that they have it. 

The FARMOVS clinical research facility on the Bloemfontein Campus of the University of the Free State is currently involved in two exciting research studies that could lead to the development of medication for diabetes sufferers burdened by some of its most common complications.

Diabetes in a nutshell

Diabetes is a group of diseases where the sugar (glucose) levels in the blood are too high. 

In diabetes mellitus (DM), the high blood-sugar levels are caused by the body not being able to control the blood-sugar levels properly, because of the body’s inability to produce or use insulin. Insulin is a hormone produced by the pancreas and lowers the blood-sugar levels by helping to move the sugar from the blood into the body cells where the sugar is used as a source of energy.

Type 1 DM is often diagnosed in children or teenagers and occurs when the pancreas does not produce any insulin. Type 2 DM occurs when the pancreas does not make enough insulin, or if the body can no longer use the insulin properly; this is often associated with poor lifestyle choices. Where this type of diabetes used to develop primarily in adults of 40 years and older, it is nowadays not uncommon for children to be diagnosed with it.


It is essential that people who are displaying one or more of the risk factors go for screening. This includes a search Physician at FARMOVS. “If DM is detected early enough, up to 90% of people don’t have to use medication but can address it through changes to their diet and exercise programmes.”

High blood-sugar levels essentially damage the blood vessels, which can lead to long-term implications for a person’s heart, kidneys, eyes, and blood circulation. 
The international studies that FARMOVS forms part of, aim to develop treatments for two of the most common secondary conditions that develop as a result of diabetes. 

Diabetic gastroparesis study

A sufferer’s intestines often don’t function properly due to the damage diabetes causes to the nerves which helps the stomach to empty properly; a condition called gastroparesis. Alleviating this condition, typically marked by abdominal pain, bloating, nausea, vomiting, and early satiety (feeling full after eating only a small amount of food), is the aim of one of the studies.

Diabetic impaired kidney function study

A second research study focuses on developing medication that will have a protective effect on a diabetic’s kidneys.  Although nothing can be done to reverse kidney damage, it is hoped that the treatment will slow down kidney degradation.

Focus on prevention

“Both of these studies are aimed at giving diabetics an increased quality of life, and by no means constitute a cure for their condition,” says Dr Van Jaarsveld.
 “The solution lies in combining the correct and committed use of medication with a decreased calorie intake and an increase in exercise – even if it’s just 30 minutes three times a week.”

Value of educating sufferers

A major benefit for participants in the FARMOVS diabetes research trials, is that they gain valuable insight in their own condition.
Diabetes has been called the ‘silent disease’, since sufferers initially have no symptoms.  For that reason, when the average patient is diagnosed with the disease, he/she already has had it for 10 years.   

For me, diabetes is such a sad disease – especially when you see patients with amputated body parts, knowing that it could have been prevented. It is really up to each individual to take responsibility for their own health,” Dr Van Jaarsveld concludes.

Diabetics who are interested in becoming part of the research studies can register online at www.farmovs.com, or contact FARMOVS at +27 51 410 3111.

News Archive

UFS Chemistry wins dti award
2010-11-02

At the awards ceremony are, from the left: Director-General of Trade and Industry Mr Tshediso Matona, Prof. Andreas Roodt and the Deputy-Minister of Trade and Industry, Ms Bongi Maria Ntuli.
Photo: S Osman

The research group of Prof. Andreas Roodt, Head of the Department of Chemistry at the University of the Free State (UFS) in Bloemfontein, won the first prize in the category Development of Small Medium and Micro-Enterprises (SMME) at the annual Department of Trade and Industry’s (dti) award ceremony.

Prof. Roodt received the prize for the high-technology project Development of novel nuclear pharmaceuticals in the Technology and Human Resources for Industry Programme (THRIP).

The Deputy-Minister of Trade and Industry Bongi Maria Ntuli, and Director-General Tshediso Matona presented the prize at the gala dinner held at Gallagher Estate, Gauteng in October 2010.

The dti’s Annual Technology Awards recognise excellence in research and aim to raise awareness on the benefits of using technology to improve the competitiveness of enterprises, within the local and global arena. Individuals and organisations are recognised for their efforts in advancing and promoting technology interests and emerging enterprises.

The technology awards cover the achievements of three of the dti technology programmes collectively, namely THRIP, managed by the National Research Foundation (NRF); the Support Programme for Industrial Innovation (SPII) managed by the Industrial Development Corporation (IDC); and the Small Enterprise Development Agency (seda) Technology Programme (stp).

Prof. Roodt, also vice-president of the European Crystallographic Association, who has just returned from a series of lectures abroad after being elected Fellow of the Royal Society of Chemistry in the UK, has received funding in excess of R3 million over the past two years to set up a specialised laboratory for synthesising active compounds. Key partners in this project are Dr Gerdus Kemp from PETLabs Pharmaceuticals in Pretoria; Prof. Connie Medlen (pharmacologist), recently appointed affiliate professor at UFS Chemistry; as well as Prof. Deon Visser from the Inorganic Chemistry research group at the UFS.

The research aims to produce new nuclear medicinal agents for the early diagnosis of cancer, heart and brain defects, and even HIV/ Aids.

Two doctoral students, Alice Brink and Marietjie Schutte, are currently actively involved in this project. They are the recipients of prestige scholarships introduced by the UFS Rector and Vice-Chancellor, Prof. Jonathan Jansen, under the UFS Research Initiative (the Advanced Biomolecular Systems Cluster) to complete their Ph.D. studies.

Media Release
Issued by: Lacea Loader
Director: Strategic Communication (actg)
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl@ufs.ac.za  
2 November 2010

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept